| Old Articles: <Older 29301-29310 Newer> |
|---|
 |
The Motley Fool
March 27, 2008
Toby Shute |
Stock Madness Elite 8: National Oilwell Varco When it comes to Stock Madness, there's no match for drilling equipment powerhouse National Oilwell Varco.   |
The Motley Fool
March 27, 2008
Anders Bylund |
Stock Madness Elite 8: Google Google goes head-to-head with the big man on campus in our Stock Madness competition. |
The Motley Fool
March 26, 2008
Mac Greer |
Fool Video: XM and Sirius vs. the Competition Will Apple be the skunk at the post-merger picnic? |
The Motley Fool
March 26, 2008
Rich Smith |
Tiffany Is Top-Drawer But is there a false bottom? Does Tiffany's stock deserve its valuation? |
The Motley Fool
March 26, 2008
Sham Gad |
When to Sell Isn't That Important The key is buying at the right price. Investors usually focus on selling instead of buying when thinking about their stock portfolio. |
The Motley Fool
March 26, 2008
Brian Lawler |
Take Two for Depomed The pharmaceutical starts another study for its proposed pain drug. The new study will double the size of patients enrolled and help reduce placebo effects. |
The Motley Fool
March 26, 2008
David Lee Smith |
Deere and Caterpillar Running Together In this whiplash-inducing market, Deere and Caterpillar can be calming. Possibilities for growth and protection exist in the machinery sector. |
The Motley Fool
March 26, 2008
Brian Orelli |
Monsanto's Guidance Grows Like a Weed The company has had good reasons to set its sights higher. Can Monsanto's current upbeat news keep going strong? |
The Motley Fool
March 26, 2008
Brian Lawler |
Celgene Brings in an Orphan The Food and Drug Administration grants a Celgene drug orphan designation. Amrubicin may have an easier time in development for use in a limited patient population. |
The Motley Fool
March 26, 2008
Todd Wenning |
Pep Boys Is Still Trying to Find Itself The tough times continue at the automotive supply retailer. |
| <Older 29301-29310 Newer> Return to current articles. |
